AIMS: Malignant transformation results in overexpression of choline-kinase (CHK) and altered choline metabolism, which is potentially detectable by immunohistochemistry (IHC). We investigated the utility of CHK-alpha (CHKA) IHC as a complement to current diagnostic investigation of prostate cancer by analysing expression patterns in normal (no evidence of malignancy) and malignant human prostate tissue samples. METHODS: As an initial validation, paraffin-embedded prostatectomy specimen blocks with both normal and malignant prostate tissue were analysed for CHKA protein and mRNA expression by western blot and quantitative reverse transcriptase PCR (qRT-PCR), respectively. Subsequently, 100 paraffin-embedded malignant prostate tumour and 25 normal prostate cores were stained for both Ki67 (labelling-index: LI) and CHKA expression. RESULTS: The validity of CHKA-antibody was verified using CHKA-transfected cells and siRNA knockdown. Immunoblotting of tissues showed good resolution of CHKA protein in malignant prostate, verifying use of the antibody for IHC. There was minimal qRT-PCR detectable CHKA mRNA in normal tissue, and conversely high expression in malignant prostate tissues. IHC of normal prostate cores showed mild (intensity) CHKA expression in only 28% (7/25) of samples with no Ki67 expression. In contrast, CHKA was expressed in all malignant prostate cores along with characteristically low proliferation (median 2% Ki67-LI; range 1-17%). Stratification of survival according to CHK intensity showed a trend towards lower progression-free survival with CHK score of 3. CONCLUSIONS: Increased expression of CHKA, detectable by IHC, is seen in malignant lesions. This relatively simple cost-effective technique (IHC) could complement current diagnostic procedures for prostate cancer and, therefore, warrants further investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: Malignant transformation results in overexpression of choline-kinase (CHK) and altered choline metabolism, which is potentially detectable by immunohistochemistry (IHC). We investigated the utility of CHK-alpha (CHKA) IHC as a complement to current diagnostic investigation of prostate cancer by analysing expression patterns in normal (no evidence of malignancy) and malignant human prostate tissue samples. METHODS: As an initial validation, paraffin-embedded prostatectomy specimen blocks with both normal and malignant prostate tissue were analysed for CHKA protein and mRNA expression by western blot and quantitative reverse transcriptase PCR (qRT-PCR), respectively. Subsequently, 100 paraffin-embedded malignant prostate tumour and 25 normal prostate cores were stained for both Ki67 (labelling-index: LI) and CHKA expression. RESULTS: The validity of CHKA-antibody was verified using CHKA-transfected cells and siRNA knockdown. Immunoblotting of tissues showed good resolution of CHKA protein in malignant prostate, verifying use of the antibody for IHC. There was minimal qRT-PCR detectable CHKA mRNA in normal tissue, and conversely high expression in malignant prostate tissues. IHC of normal prostate cores showed mild (intensity) CHKA expression in only 28% (7/25) of samples with no Ki67 expression. In contrast, CHKA was expressed in all malignant prostate cores along with characteristically low proliferation (median 2% Ki67-LI; range 1-17%). Stratification of survival according to CHK intensity showed a trend towards lower progression-free survival with CHK score of 3. CONCLUSIONS: Increased expression of CHKA, detectable by IHC, is seen in malignant lesions. This relatively simple cost-effective technique (IHC) could complement current diagnostic procedures for prostate cancer and, therefore, warrants further investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Geoffrey Alan Watson; Enrique Sanz-Garcia; Lillian L Siu; Eric Chen; Wen-Jiang Zhang; Zhihui Amy Liu; Sy Cindy Yang; Ben Wang; Shaofeng Liu; Shawn Kubli; Hal Berman; Thomas Pfister; Sofia Genta; Anna Spreafico; Aaron R Hansen; Philippe L Bedard; Stephanie Lheureux; Albiruni Abdul Razak; Dave Cescon; Marcus O Butler; Wei Xu; Tak W Mak Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Chad A Reichard; Bryan D Naelitz; Zeneng Wang; Xun Jia; Jianbo Li; Meir J Stampfer; Eric A Klein; Stanley L Hazen; Nima Sharifi Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-28 Impact factor: 4.090
Authors: Cordula A Jilg; Vanessa Drendel; H Christian Rischke; Teresa I Beck; Kathrin Reichel; Malte Krönig; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Philipp T Meyer; Werner Vach Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057
Authors: Sebastian Trousil; Maciej Kaliszczak; Zachary Schug; Quang-De Nguyen; Giampaolo Tomasi; Rosy Favicchio; Diana Brickute; Robin Fortt; Frazer J Twyman; Laurence Carroll; Andrew Kalusa; Naveenan Navaratnam; Thomas Adejumo; David Carling; Eyal Gottlieb; Eric O Aboagye Journal: Oncotarget Date: 2016-06-14